[Results of calcitonin therapy of the painful symptoms caused by osteolytic metastases of prostatic carcinoma].
Albeit within the limits imposed on us by the restricted number of cases, we can state that--in the present state of research--calcitonin constitutes a useful complement in treatment of osteolytic metastasis induced by carcinoma of the prostate. Is utilisation is justified by the effects observed: on the one hand, osteogenesis as a factor protecting against the aggressivity of the tumoural cells, and on the other the considerable antalgic strength allied with improvement in the calcium, phosphorus and phosphatase values. For some time we have replaced pig calcitonin with salmon calcitonin: the comparative results with this second product will be the subject of a subsequent paper.
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002116:Calcitonin / Q000627:therapeutic use*; D008297:Male; D010014:Osteolysis / Q000150:complications; D010146:Pain / Q000188:drug therapy*; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000150:complications*
D002116:Calcitonin
Risultati della terapia con calcitonina sulla sintomatologia dolorosa da metastasi osteolitiche di carcinoma prostatico.